Stay in touch
Prime news from our network.
#read
BioNTech announces progress with mRNA cancer vaccine
BioNTech has announced initial positive results from a Phase 2 study of its mRNA immunotherapy candidate BNT111. The study showed a significant improvement in the overall response rate in patients with advanced melanoma who received BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab.
30/07/2024
The drug showed an increased rate of tumour regression. BioNTech is developing a total of 41 potential drugs, two of which are in the final clinical phase. In view of Covid's rapid sales, the success of the cancer drugs is of crucial importance to the company. The first cancer drug is expected to be launched in 2026. One ADC candidate is experiencing problems with deaths in the Phase 1 trial, which is why the FDA has halted the trial.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.